VYNE
insider transactionsVYNE Therapeutics Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
Transactions · 365d
-
Grant·A
Domzalski David KEY
PRESIDENT AND CEO
$9.5K
30.8K sh · $0.31
Own +8%
-
Other·F
Zeronda Tyler KEY
CHIEF FINANCIAL OFFICER
$2.4K
4.0K sh · $0.60
Own -4%
-
Other·F
CHIEF SCIENTIFIC OFFICER
$1.7K
2.9K sh · $0.60
Own -2%
-
Other·F
CHIEF LEGAL OFFICER AND GC
$2.4K
4.0K sh · $0.60
Own -3%
-
Other·F
Domzalski David KEY
PRESIDENT AND CEO
$8.5K
14.2K sh · $0.60
Own -3%
-
Other·F
CHIEF LEGAL OFFICER AND GC
$2.1K
3.6K sh · $0.58
Own -3%
-
Other·F
CHIEF SCIENTIFIC OFFICER
$1.4K
2.4K sh · $0.58
Own -2%
-
Other·F
Domzalski David KEY
PRESIDENT AND CEO
$7.4K
12.7K sh · $0.58
Own -3%
-
Other·F
Zeronda Tyler KEY
CHIEF FINANCIAL OFFICER
$4.6K
7.9K sh · $0.58
Own -7%
-
Grant·A
Director
$0
20.0K sh
Own New
-
Grant·A
Director
$0
20.0K sh
Own New
-
Grant·A
Director
$0
20.0K sh
Own New
-
Grant·A
Director
$0
20.0K sh
Own New
-
Other·F
CHIEF SCIENTIFIC OFFICER
$834
2.5K sh · $0.34
Own -2%
-
Other·F
CHIEF LEGAL OFFICER AND GC
$1.2K
3.6K sh · $0.34
Own -3%
-
Other·F
Zeronda Tyler KEY
CHIEF FINANCIAL OFFICER
$1.2K
3.4K sh · $0.34
Own -3%
-
Other·F
Domzalski David KEY
PRESIDENT AND CEO
$4.3K
12.7K sh · $0.34
Own -3%
-
Other·F
Zeronda Tyler KEY
CHIEF FINANCIAL OFFICER
$5.6K
3.4K sh · $1.65
Own -3%
-
Other·F
Domzalski David KEY
PRESIDENT AND CEO
$20.9K
12.7K sh · $1.65
Own -3%
-
Other·F
CHIEF SCIENTIFIC OFFICER
$4.0K
2.5K sh · $1.65
Own -2%
-
Other·F
CHIEF LEGAL OFFICER AND GC
$5.9K
3.6K sh · $1.65
Own -3%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 29, 2026 | Domzalski David KEY | Grant A | 30.8K | $9.5K |
| Mar 31, 2026 | Zeronda Tyler KEY | Other F | 4.0K | $2.4K |
| Mar 31, 2026 | Stuart Iain | Other F | 2.9K | $1.7K |
| Mar 31, 2026 | Harsch Mutya | Other F | 4.0K | $2.4K |
| Mar 31, 2026 | Domzalski David KEY | Other F | 14.2K | $8.5K |
| Dec 31, 2025 | Harsch Mutya | Other F | 3.6K | $2.1K |
| Dec 31, 2025 | Stuart Iain | Other F | 2.4K | $1.4K |
| Dec 31, 2025 | Domzalski David KEY | Other F | 12.7K | $7.4K |
| Dec 31, 2025 | Zeronda Tyler KEY | Other F | 7.9K | $4.6K |
| Dec 12, 2025 | LEPORE PATRICK G | Grant A | 20.0K | $0 |
| Dec 12, 2025 | Unknown | Grant A | 20.0K | $0 |
| Dec 12, 2025 | BARBARI SHARON | Grant A | 20.0K | $0 |
| Dec 12, 2025 | Sandoval Elisabeth | Grant A | 20.0K | $0 |
| Sep 30, 2025 | Stuart Iain | Other F | 2.5K | $834 |
| Sep 30, 2025 | Harsch Mutya | Other F | 3.6K | $1.2K |
| Sep 30, 2025 | Zeronda Tyler KEY | Other F | 3.4K | $1.2K |
| Sep 30, 2025 | Domzalski David KEY | Other F | 12.7K | $4.3K |
| Jun 30, 2025 | Zeronda Tyler KEY | Other F | 3.4K | $5.6K |
| Jun 30, 2025 | Domzalski David KEY | Other F | 12.7K | $20.9K |
| Jun 30, 2025 | Stuart Iain | Other F | 2.5K | $4.0K |
| Jun 30, 2025 | Harsch Mutya | Other F | 3.6K | $5.9K |
Buy Sell Non-market (grant · exercise · gift)
About VYNE insider trading
This page tracks insider transactions for VYNE Therapeutics Inc. (VYNE) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.